CYAD-211

CYAD-211 is a non-gene edited, allogeneic CAR T-cell therapy candidate designed for the treatment of relapsed or refractory multiple myeloma. It consists of human donor-derived T lymphocytes engineered to co-express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), along with a single optimized short hairpin RNA (shRNA) that downregulates the expression of the CD3ζ subunit of the T-cell receptor complex. This shRNA-mediated knockdown minimizes surface TCR expression, reducing the risk of graft-versus-host disease (GvHD). The product also includes a truncated CD34 selection marker for cell tracking and enrichment. CYAD-211 is being developed as an "off-the-shelf" therapy to overcome limitations associated with autologous and gene-edited allogeneic CAR-T approaches[1][2][3][6][8]. **Developers:** Celyad Oncology CYAD-211 is notable as one of the first non-gene edited allogeneic CAR-T therapies using shRNA technology to minimize GvHD risk by silencing endogenous TCR signaling. Its primary clinical development focus has been in relapsed/refractory multiple myeloma; no brand or generic names are currently established beyond its code name.

Other names

BCMA-CAR T cells with CD3ζ shRNA